Aligos Therapeutics (ALGS) Operating Leases (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Operating Leases for 8 consecutive years, with $288000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 91.04% year-over-year to $288000.0; the trailing twelve-month figure through Jun 2026 stood at $288000.0 (down 91.04% YoY), and the FY2025 full-year result was $1.5 million, down 68.2% from the prior year.
• Operating Leases eased to $288000.0 in Q2 2026 per ALGS's latest filing, from $659000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $10.9 million in Q1 2022 and bottomed at $288000.0 in Q2 2026.
• Historically, Operating Leases has averaged $6.1 million across 5 years, with a median of $6.6 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Operating Leases increased 6.56% in 2022, then plunged 91.04% in 2026.
• Over 5 years, Operating Leases stood at $9.2 million in 2022, then fell by 16.66% to $7.7 million in 2023, then sank by 37.47% to $4.8 million in 2024, then tumbled by 68.2% to $1.5 million in 2025, then tumbled by 81.11% to $288000.0 in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $288000.0, $659000.0, and $1.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.